ACADIA Pharmaceuticals Soars on Early Approval of Parkinson’s Treatment

Michael Teague |

ACADIA Pharmaceuticals (ACAD) was up 55.60 percent on Thursday, with shares trading as for as much as $12.40, after Wednesday’s closing price of $7.97.

ACADIA makes drugs that treat neurological and central nervous system-related disorders. Currently, the company is developing pimavanserin for the treatment of Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia.



The $934.86 million market-cap company’s performance was sparked by the announcement that its pimavanserin Parkinson’s disease psychosis treatment qualifies for the filing of a New Drug Application (NDA) without requiring the customary final-phase trial that was scheduled to commence later in the month.

For as many as 40 percent of those with advanced-stage Parkinson’s disease, psychosis is a commonly experienced complication, often in the form of visual hallucinations. Furthermore, Parkinson’s-related psychosis can be induced by more or less all drugs used to treat the disease.

In a statement released earlier in the day, the company said that the Food and Drug Administration “has agreed that the data from the pivotal Phase III -020 study, together with supportive data from other studies with pimavanserin, are sufficient to support the filing.”

ACADIA will now have to finish up testing and studies, and plans to submit the NDA request by the end of 2014.

Company CEO Dr. Uli Hacksell was quoted in the company’s statement as being happy with the FDA’s decision, saying that it “will reduce substantially both the time and cost of our PDP development program.”

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Companies

Symbol Name Price Change % Volume
ACAD ACADIA Pharmaceuticals Inc. 35.78 -0.54 -1.49 969,597 Trade
WAG26 Walgreens Boots Alliance Inc 2.125% Eur Nt Due 202 n/a n/a n/a 0 Trade

Comments

Emerging Growth

Invictus MD Strategies Corp

Invictus MD Strategies Corp is engaged in the investment, acquisition and development of synergistic businesses in an effort to increase and sustain growth and value.

Private Markets

iPRO Network, LLC

We provide the platform, tools, and resources to empower individuals and professionals to market desirable goods and services to the public, taking the place of traditional methods of commerce.

The Green Organic Dutchman

The Green Organic Dutchman Ltd. ("TGOD") produces farm grown, organic cannabis for medical use. The company grows its high quality organic cannabis in small batches using craft growing, all natural…